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Background: Intracranial aneurysm (IA) is one of the most lethal forms of cerebrovascular diseases characterized by
endothelial dysfunction, vascular smooth muscle cell phenotypic modulation, inflammation and consequently loss
of vessel cells and extracellular matrix degradation. Besides environmental factors, genetics seem to be a very
important factor in the genesis of this disease. Previous mRNA expression studies revealed a large number of
differentially expressed genes between IA and control tissue. However, microRNAs (miRNA), small non-coding RNAs
which are post-transcriptional regulators of gene expression, have been barely studied. Studying miRNAs could
provide a hypothetical mechanism underlying rupture of IA.
Methods: A microarray study was carried out to determine difference in microRNAs and mRNA between patients’
IA tissues and controls. Quantitative RT-PCR assay compared the expression level between two groups (14 IA
domes vs. 14 controls) were used for validation. Validated miRNAs were analyzed using Ingenuity Pathway Analysis
(IPA) to identify the networks and pathways.
Results: 18 miRNAs were confirmed by qPCR to be robustly down-regulated in 14 ruptured IA patients including
hsa-mir-133b, hsa-mir-133a, hsa-mir-1, hsa-mir-143-3p, hsa-mir-145-3p, hsa-mir-145-5p, hsa-mir-455-5p, hsa-mir-143-5p,
hsa-mir-23b-3p etc., of which 11 miRNAs are clusters: hsa-mir-1/has-mir-133a, hsa-mir-143/hsa-mir-145, hsa-mir-23b/
hsa-mir-24-1, and hsa-mir-29b-2/hsa-mir-29c. 12 predicted functions were generated using IPA which showed significant
associations with migration of phagocytes, proliferation of mononuclear leukocytes, cell movement of mononuclear
leukocytes, cell movement of smooth muscle cells etc.
Conclusion: These data support common disease mechanisms that may be under miRNA control and provide exciting
directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new
therapies for IA.
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As one of the most devastating neurological conditions
known to date, intracranial aneurysm (IA) has a high mor-
tality rate and undesirable prognosis with spontaneous
cerebral hemorrhage, cerebral vasospasm, and oculomotor
nerve palsy as the main clinical feature. IA is common re-
sult of vascular abnormalities in the brain, with a preva-
lence of 3.2% in the general population, and an overall risk
of rupture around 1.2% in western populations and 2.3% in* Correspondence: lijia@sklmg.edu.cn; duanranhui@sklmg.edu.cn
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reproduction in any medium, provided the orJapanese series [1]. A significant proportion of aneurysmal
patients are around the age of 40–60 [2,3]. Cigarette smok-
ing, excessive alcohol consumption, hypertension and fe-
male gender are significant risk factors for IA formation
and growth, and family history of IA has also been sug-
gested to be evidence for genetic causality of cerebral aneu-
rysms. Dysfunction of vessel cells, degeneration of vessel
wall and activation of immune system were identified to be
the intrinsic factors of IA development [3-6]. Its unpredic-
table nature and the catastrophic consequences of IA rup-
ture remain a challenge for clinicians. Comprehensive
understanding of IA pathobiology is crucial for reasonable
management of IA carriers.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and human aneurysmal tissues are difficult to obtain, the
molecular mechanisms of IA remain poorly understood.
Most studies focus on mRNA expression in aneurysmal
and healthy tissue to identify the alteration of gene expres-
sion within the vessel wall, which has implied some mech-
anisms underlying the development of IA. For example, in
2008 Krischek et al. found differentially expressed genes,
which indicated that antigen processing was the most
significantly associated; another study in 2009 by Shi et al.
indicated that misregulated genes were mostly correlated
with focal adhesion, ECM-receptor and cell communica-
tion etc. Because the large amounts of data created with
each study, make a comparison or interpretation of results
difficult, Roder et al. (2012) performed a meta-analysis
which found seven genes showing altered expression in
more than three studies: BCL2, COL1A2, COL3A1, COL
5A2, CXCL12, TIMP4, TNC [7-13]. Functional studies on
these genes showed that COL1A2, COL3A1, COL5A2,
TIMP4, and TNC could modulate processes in the forma-
tion of the extracellular matrix (ECM), which have been
described in association with IAs [10,14]. miRNA may be
another layer of control in gene expression which modu-
lates pathways and mechanisms of IA, however, expres-
sion of miRNA in IA is rarely studied.
A novel direction for IA research is the modulation
of miRNA, endogenous approximately 23 nt non-coding
RNAs. By binding to the 3’ UTR of complementary
protein-coding mRNAs, miRNA primarily acts in the post-
transcriptional repression of gene expression in animals
and plants. miRNAs are incorporated into the RNA in-
duced silencing complex (RISC) and then inhibit gene
expression by either mRNA degradation or inhibiting
translation which can thereby regulate up to 75% of the
human genome which belong to many biological path-
ways including immune response and apoptosis [15-19].
Dysregulation of miRNAs have been found to have rele-
vance to tumorigenesis, neurological, cardiovascular and
developmental and other diseases [20]. Recent studies
have demonstrated that miRNAs play roles in vascular re-
modelling and atherosclerosis [21,22]. miRNA may be an-
other layer of control in gene expression which modulates
pathways and mechanisms of IA, however, expression of
miRNA in IA is rarely studied.
The role of miRNA in the molecular mechanism of IA
has been of particular interest. Our study focused on in-
vestigating how the differential expression patterns of re-
gulatory microRNAs in IA act as a potential regulator
in its pathological mechanism. We generated a microRNA
array followed by confirmation of miRNAs individually
with qRT-PCR. We identified 18 miRNAs in 14 patients
which were significantly down-regulated between IA and
control tissue, 11 of these miRNAs in the cluster includ-
ing hsa-mir-1/has-mir-133a, hsa-mir-143/hsa-mir-145, hsa-mir-23b/hsa-mir-24-1, hsa-mir-29b-2/hsa-mir-29c. Func-
tional analysis indicates these miRNAs are involved with
dysfunction and remolding of vascular endothelial cells,
vascular smooth muscle cell and involvement of inflamma-
tory/immune processes.
Methods
Patients and tissue samples
Full-thickness vessel wall samples from 14 ruptured IA
domes were prospectively collected from patients (10 fe-
male, 4 male, age: 52.7 ± 8.5 ) undergoing microsurgical
clipping. 14 middle meningeal artery (MMA) segments
with matched sex and age were obtained during standard
neurosurgical procedures (traumatic hematoma, tumor re-
section, IA clipping) as control. Written informed consent
for participation in the study was obtained from patients.
Tissue samples were snap frozen in liquid nitrogen and
directly sent to the laboratory to perform RNA extraction.
The collection of the human tissues was approved by
Ethical Committee of the Second Xiangya Hospital of
Central South, China.
Extract RNA from samples
The total RNA was extracted by Trizol Reagent. RNA con-
centration and purity were determined using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Tech, Rockland,
DE), with a 260/280 value >1.8 considered acceptable. RNA
samples were further assessed for quality using a Agilent
2100 Bioanalyzer (Agilent Technologies, Foster City, CA)
according to the manufacturer’s instructions to ensure an
RNA integrity number > 7, and RNA samples for Agilent
miRNA Chip: RIN ≥ 6.0 and 28S/18S>0.7 was used.
Determination of specific miRNAs
miRNA microarray profile was performed using Agilent
microRNA array 16.0 (3 aneurysmal wall samples and 3
healthy control samples) to identify candidate microRNAs
expressed differently between patients’ IA tissues and con-
trols. Agilent Whole Human Genome Oligo Microarray
(4 × 44 K) was used for mRNA expression (2 aneurysmal
wall samples and 2 healthy control samples). The micro-
array data can be obtained at the Gene Expression Omni-
bus (GEO) database (GSE46338 is the reference Series;
http://www.ncbi.nlm.nih.gov/geo/).
Confirmation of miRNA expression
miRNA and mRNA profile data were screened, keeping
data with a change of more than 2 fold, then we verified
the screened miRNA by RTq-PCR (SYBR® PrimeScript™
miRNA RT-PCR Kit (RR716)) according to manufactu-
rer’s recommendation. Quantitative RT-PCR reactions were
completed on CFX96™ Real-Time System. The relative ex-
pression levels of the miRNAs were calculated using the -
ΔΔCT method and relative miRNA levels were normalized
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pression level between two groups (14 IA domes vs. 14
controls). For the data obtained by qRT-PCR, the Mann–
Whitney test and Student's t-test were used for the com-
parison between IA and control, and differences were
considered to be significant when p < 0.05. Samples were
run in triplicate and the average values were used in sub-
sequent analysis.
Function analysis
The selected miRNAs were further analyzed to identify the
networks and pathways. For this purpose, we used software
Ingenuity Pathway analysis (IPA, Ingenuity® Systems; http://
www.ingenuity.com). This pathway analysis software identi-
fies the putative targets for the input miRNA(s), integrates
with our mRNA microarray profiles data, and then de-
velops the networks and functions among the genes/targets.
Before starting the analysis, miRNA targets (confidence was
set to “highly predicted” and “experimental observed”,
species was chosen to “human”) were predicted by an
integrated database including miRecords, Tarbase and
TargetScan Human. Then the high predicted targets were
matched and paired with mRNA expression data by the ex-
pression pairing function of IPA. We assume that the
expression of a given miRNA is anti-correlated with the
mRNA expression of its targets. This is a widely accepted
and experimentally verified supposition [23]. The results
which provide us mainly with bio-functions and canonical
pathways associated with our data had been generated
automatically using the option of core-analysis in IPA.
Results
Identification of differently expressed miRNAs in IA
Focusing initially miRNA profiling data on IA tissues vs.
normal tissues, there were 30 (FDR p < 0.05, ± 2 fold)
differentially regulated miRNAs out of 1500 microRNAs.
Among the 30 miRNAs identified, 29 were down-regulated
in the IA tissue and 1 was upregulated. miRNAs identified
in the microarray study were validated using individual
real-time qRT-PCR assays. And 18 were found to be signifi-
cantly different between the IA and control groups of the
14 patients (FC > 2 or FC < −2), and the p-value and FC
were calculated (Table 1), miR-142-5p was upregulated in
microarray profile, but qRT-PCR result showed no signifi-
cance between IAs and controls (P = 0.25). The rest of
the candidate miRNAs showed an expression tendency
consistent with the array result, but without statistical
significance.
The expression levels of hsa-mir-1, hsa-mir-7-1-3p, hsa-
mir-23b-5p, hsa-mir-23b-3p, hsa-mir-24-1-5p, hsa-mir-28-
5p, hsa-mir-28-3p, hsa-mir-29b-2-5p, hsa-mir-29c-5p, hsa-
mir-29c-3p, hsa-mir-133a, hsa-mir-133b, hsa-mir-140-3p,
hsa-mir-143-5p, hsa-mir-143-3p, hsa-mir-145-5p, hsa-mir-
145-3p, hsa-mir-455-5p were down-regulated at least twofold in IA compared with the control group (Figure 1).
There are 4 clusters among those miRNAs: hsa-mir-1/has-
mir-133a (chr18), hsa-mir-143/hsa-mir-145 (chr5), hsa-mir-
23b/hsa-mir-24-1 (chr9), hsa-mir-29b-2/hsa-mir-29c (chr1).
Some miRNAs play a role in the cardiovascular system.
For example, miR-1 is induced during smooth muscle cell
(SMC) differentiation and increases the expression of
SMC-specific contractile proteins. miR-133 is a key regu-
lator of vascular smooth muscle cell phenotypic switch
in vitro and in vivo [24]. Also notable, miR-145 is related
to the thickness of the vessel wall, and the absence of
miR-145 could reduce the vessel thickness and due to
hypotrophy of SMCs [25]. miR-145 is down-regulated fol-
lowing vascular injury, during atherosclerosis, and in ex-
perimentally induced aneurysms [26,27].
Integrated analysis of misregulated miRNAs and mRNAs
miRNAs modulate gene expression through both mRNA
degradation and translational repression mechanisms, and
miRNA-mRNA regulatory networks are highly complex.
A dataset of 681 genes created from our mRNA micro-
array data paired with high predicted and experimentally
observed targets to 18 miRNAs, which were used for In-
genuity Pathway Analysis (IPA). IPA results revealed top
functions of these 681 common targets. The most im-
pacted biological processes for IA including: migration of
phagocytes, proliferation of mononuclear leukocytes, cell
movement of mononuclear leukocytes, cell movement of
smooth muscle cells, differentiation of macrophages etc.
(Table 1). The functions are chosen and arranged by the
z-score which indicates the predicted degree of those
functions. A positive value means an increase in the func-
tion, while a negative value means a decrease the function,
and the p-value indicates the significance of each function.
IPA predicted the most impacted biological processes
for IA based on the miRNAs and their targets. 54 genes
and 11 miRNAs were involved in the top 12 predicted
functions, and a network generated by IPA showed the
interactions between those miRNAs and mRNA (Figure 2).
Some distinctive genes shown in the network targeted
by more than 3 miRNAs include Kruppel-like factors
4 (KLF4); inducible T cell co-stimulator (ICOS); CD28,
Mitogen-activated protein kinase 1 (MAPK1); and colla-
gen, type IV, alpha 3 (COL4A3). Notably, among the dif-
ferentially expressed mRNAs predicted to be targeted by
the differential miRNAs, were some genes previously ex-
perimentally identified to be involved in aneurysm forma-
tion or loss of vessel cells, such as TGFBR1, MMPs and
IL18 etc. [28,29].
KLF4 plays roles in cell proliferation, differentiation and
survival. Its role, especially in the context of cancer, has
been extensively studied, and several studies have explored
the role of KLF4 in vascular smooth muscle cell and vas-
cular endothelial cell. ICOS belongs to the CD28 and
Table 1 Network of the interactions of the miRNA target genes
Category Genes Upstream miRNAs Z-score/ p-value
Migration of Phagocytes CCL2, CCL7, CD40, CSF1, FN1, MMP14, PLAU,
PLXND1, SERPINE1, SOCS3
mir-1, mir-133, mir-143-3p, mir-145-5p, mir-23a-3p,
mir-28-5p, mir-455-5p
2.627/1.05E-2
Proliferation of Mononuclear Leukocytes ANPEP, CD1D, CD276, CD28, CD40, CD84, CSF1, DPP4, FN1,
FTL, ICOS, IL18, IL2RA, KLF4, KLRC4-KLRK1/KLRK, LILRB1, MYC,
PIM1, PNP, PTPRJ, THBS1, TIGIT, TNFRSF10B, TNFRSF9, TNFSF13, ULBP2




Cell Movement of Mononuclear Leukocytes ADAM17, CCL2, CCL7, CD28, F11R, FN1, ICOS, IL18, ITGAL, MMP14,
PDGFB, PLAU, PTPRO, RGS1, SERPINE1, SOCS3, THBS1, TLR4
mir-1, mir-133, mir-140-3p, mir-143-3p, mir-145-5p,
mir-23a-3p, mir-28-3p, mir-28-5p, mir-29b-3p, mir-455-5p
2.316/2.66E-3
Cell Movement of Smooth Muscle cells CCL2, CSF1, FN1, IL18, PLAU, PTGS2, THBS1, TRIB1 mir-1, mir-143-3p, mir-23a-3p, mir-28-5p 2.201/1.20E-3
Differentiation of Macrophages CDC42, CSF1, LIF, MYB, PRDM1, TLR4 mir-133, mir-140-3p, mir-145-5p, mir-23a-3p,
mir-28-5p, mir-29b-3p
2.166/5.70E-3
Stimulation of T Lymphocytes CD28, CD40, DPP4, FN1, ICOS, IL18, KLRC4-KLRK1/KLRK1 mir-1, mir-133, mir-143-3p, mir-145-5p, mir-28-3p,
mir-28-5p, mir-29-3p,
2.000/7.39E-5
Cell Death of Vascular Endothelial Cells BCL2L1, IL18, LRP1, MAPK1, PMAIP1, THBS1, TNFRSF10B, TNFSF15 mir-1, mir-133, mir-143-3p, mir-143-5p,
mir-23a-3p, mir-28-5p,
1.811/4.47E-3
Migration of Endothelial Cells CCL2, COL4A1, DPP4, FN1, HOXA9, MMP14, NRP1, PDGFB, PIM1,
PTGS2, SCARB1, SCG2, SERPINE1,TGFBR1,THBS1,TNFSF15
mir-1, mir-133, mir-143-3p, mir-145-5p, mir-23a-3p,
mir-29b-3p
1.610/2.19E-3
Cell Movement of Endothelial Cells ANPEP, CCL2, CDH2, COL4A1, DPP4, FN1, HOXA9, MMP14, NRP1, PDGFB,
PIM1, PTGS2, SCARB1, SCG2, SERPINE1, TGFBR1, THBS1, TNFSF15
mir-1, mir-133, mir-143-3p, mir-145-5p,
mir-23a-3p, mir-29b-3p
1.606/8.83E-4
Apoptosis of Vascular Endothelial Cells BCL2L1, IL18, LRP1, MAPK1, PMAIP1, THBS1, TNFRSF10B mir-1, mir-133, mir-140-3p, mir-143-3p,
mir-145-5p, mir-23a-3p, mir-28-5p
1.525/1.02E-2
Proliferation of Smooth Muscle Cells CCL2, FOS, MAPK1, PDGFB, SERPINE1, ST8SIA1, THBS1, TLR4, TNFAIP3, TRIB1 mir-1, mir-143-3p, mir-140-3p, mir-145-5p,
mir-23a-3p, mir-28-5p, mir-29b-3p, mir-455-5p
1.037/1.83E-3
Proliferation of Endothelial Cells CDH2, COL4A1, COL4A3, CSF1, DAB2, F11R, FN1, LPAR2, NRP1, PDGFB,
PIM1, SCG2, TGFBR1, THBS1, TNFSF15
mir-1, mir-133, mir-140-3p, mir-143-3p,
mir-145-5p, mir-23a-3p, mir-28-5p, mir-29b-3p
−1.600/3.16E-3
The P value indicates the likelihood of the focus genes in a network being found together as a result of random chance. Using a 99% confidence level, z-scores of 2 were considered significant. Significances for the
enrichment of the genes in a network with particular biologic functions or canonical pathways were determined via right-tailed Fisher’s exact test and the whole database as a reference set. The same computation




















Figure 2 A network of the interactions of the miRNAs and their target genes (experimental observed or highly predicted). Ingenuity
Pathway Analysis® tool was used to generate miRNA–mRNA interactions of miR-1, miR-133, miR-140-3p, miR-143-3p, miR-145-5p and, miR-23a-3p,
miR-28-3p, miR-28-5p, miR-29b-3p and their targets in all selected functions. Red and green color represents the molecules to be upregulated
and down-regulated respectively.
Figure 1 Validation of microarray results by real-time qRT-PCR in a set of samples (n = 14). 18 miRNAs identified as significantly different
between IA and controls in the microarray study were evaluated by qRT-PCR in 14 IA and 14 control samples (MMA).
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http://www.biomedcentral.com/1755-8794/6/36CTLA-4 cell-surface receptor family, and it plays an im-
portant role in cell-cell signaling, immune responses, and
regulation of cell proliferation. ICOS also has been found
to function in vascular diseases such as atherosclerosis
[30]. CD28 is essential for T-cell proliferation and survival,
cytokine production, and T-helper type-2 development.
A recent study has shown that CD28 influence the ath-
erosclerosis development by co-stimulating T-cell with
CD80/86 [31]. MAPK1 is a component of MAP kinase
family which is involved in a wide variety of cellular pro-
cesses such as proliferation, differentiation, and transcrip-
tion regulation and development. Many researchers have
determined the MAPK signaling participate in the bio-
logical processes of vascular system such as proliferation
of vascular endothelial cell [32] and vascular damage [33].
COL4A3 is a subunit of Type IV collagen and is the major
structural component of basement membranes. Investigat-
ing these targets in this network may provide new com-
pensatory mechanisms for protecting against IA, and may
also be characterized in future studies to contribute to the
miRNA-regulated response mechanisms following IA.
The mechanism that underlies the formation and de-
velopment of IA is complicated and partly understood.
In order to demonstrate our result more distinctively, we
drew a schematic diagram to list three most impactedFigure 3 Biological categories of miRNA and predicted functions.aspects of IA [3,5] in black box (Figure 3). Dysfunction of
vascular endothelial cell (VEC), modulation of vascular
smooth muscle cell (VSMC) and inflammatory response
were identified to be the intrinsic factors of IA develop-
ment. Several branches are connected to a red box with
the name of the relevant function, genes involved in and
z-score/p-value. Another green box contain the miRNAs
which target the corresponding genes in the function is at-
tached to the red one. Among those functions, migration
of phagocytes has the highest z-score about 2.627, which
means the function could have the maximum extent of ac-
tivation based on the genes (CCL2, CCL7, CD40, CSF1,
FN1, MMP14, PLAU, PLXND1, SERPINE1, SOCS3) , and
those genes are validated or highly predicted targets of
mir-145-5p, mir-23a-3p, mir-143-3p, mir-133, mir-28-5p,
mir-1, mir-455-5p.
Discussion
IA is the most fatal cerebrovascular system disease. Mech-
anisms underlying formation, progression, and rupture of
IA are complex and involve a multitude of processes that
are not completely understood. No safe and effective non-
invasive therapies have been applied in clinical practice
until recently. Treatments currently available include sur-
gical (clipping) and endovascular (such as coiling), which
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circulation, but potentially serious complications [4]. Nu-
merous efforts made to uncover the biology of IA have
suggested that aneurysm is caused by a combination of
hemodynamic stresses and defective vessel wall responses
[34]. In recent years, prominent roles for microRNAs
(miRNAs) have been revealed in several vascular disor-
ders, several miRNAs have been found to be critical mod-
ulators of vascular pathologies, such as atherosclerosis,
lipoprotein metabolism, inflammation, arterial remodeling,
angiogenesis, smooth muscle cell regeneration, hyperten-
sion, apoptosis, neointimal hyperplasia and signal trans-
duction pathways [35]. miRNAs may also serve as novel
biomarkers and/or therapeutic targets for vascular disease
[36-38]. Determining miRNA regulatory role and investi-
gating the molecular mechanisms will expand our know-
ledge to better understand IA by analyzing miRNA
mediated pathways.
We found that 18 miRNAs were significantly down-
regulated in IA domes of 14 ruptured IA patients. There
are 4 clusters among 18 miRNAs according to mirBase
(www.mirbase.org): hsa-mir-1/has-mir-133a, hsa-mir-143/
hsa-mir-145, hsa-mir-23b/hsa-mir-24-1, hsa-mir-29b-2/h
sa-mira-29c. We searched the literature for information
on the 18 miRNAs. miR-1, miR-133, miR-143, miR-145
are highly expressed miRs in SMCs and have been found
to regulate the SMC phenotype [39-44]. miR-1 is induced
during SMC differentiation and increases the expression
of SMC-specific contractile proteins by targeting KLF4
[45]. Notably, the interaction which is critical for modula-
tion of vascular smooth muscle cell phenotype, between
KLF4 and miR-143/145 has also been identified [46,47];
miR-133 impairs the proliferation of SMCs and inhibits
the PDGF-induced switch towards a synthetic SMC phe-
notype by repressing the transcription factor Sp-1 [48].
Several recent studies describe the involvement of miR-29
in aneurysm formation by post-transcriptionally repressing
the expression of extracellular matrix proteins such as
collagens, elastin, and fibrillins [49-54]. Several genome-
wide linkage studies have determined some disease-related
loci such as chr1p34.3–p36.13, chr7q11, chr19q13.3, and
chrXp22 underlying the development of IA [55]. One
study which is worth noting has identified several loci in
familial IAs, miR-133a-1/miR-1-2 locates at chromosomes
18q11.2 which is strongly associated with the development
of intracranial aneurysms [56].
miRNAs may function as provital regulators of biological
processes during IA development by regulating down-
stream genes. A meta-analysis of five microarray gene ex-
pression studies of 60 samples revealed seven genes: BCL2,
COL1A2, COL3A1, COL5A2, CXCL12, TIMP4, TNC that
are very likely to be involved in the genesis of IAs [57].
These genes are also upregulated more than two fold in
our samples. BCL2 is targeted by miR-143 in cervicalcancer, which is involved in apoptosis and tumor forma-
tion; miR-1 regulates cardiomyocyte apoptosis by targeting
BCL2 [58,59]. miR-1 is able to inhibit thyroid carcinoma
cell proliferation and migration by targeting CCND2, CX
CR4 and CXCL12 [60]. COL1A2, COL3A1, COL5A2 are a
group of collagen genes in which mutations are associated
with several connective diseases such as the involvement of
COL3A1 mutations in intracranial aneurysms and Ehlers-
Danlos syndrome type IV with aortic and arterial aneu-
rysms [61,62]. miR-29 targeted several extracellular matrix
genes including COL1A2, COL3A1 and COL5A2, and has
been validated in nasopharyngeal carcinomas and HTM
(human trabecular meshwork) cells [63,64]. Another study
has observed that COL3A1 is targeted by miR-29 as a par-
ticipant in the mechanism of atrial fibrillation [65].
A break in the delicate balance between local hemody-
namic stress and arterial wall integrity may be the reason
why IA occurs. Genesis of IA may be triggered by aberrant
flow conditions, and a group of activated cells could lead
to an unstable situation between “repair and maintain” and
“degrade and destroy”, following which dysfunction of
endothelial cell, and loss of mural cell and inflammatory
response may eventually lead IA rupture [3]. Lots of cells
and genes are abnormally modulated during the develop-
ment of IA, investigating those miRNA or mRNA found in
our study and their regulating networks may provide new
insight of IA pathogenesis.
Analysis generated by IPA on those validated miRNAs
and their putative targets revealed that these miRNAs
may be involved in the three main pathological pro-
cesses: loss of vessel cells, phenotypic change of vessel
cells, and inflammation of the vessel. Several targets of
miRNAs have been reported to function in the loss of
vessel cells which is the main characteristic of the late
stages of the human aneurysmal disease. For example,
Thrombospondin 1 (THBS1), also known as TSP-1,
targeted by miR-1 [66], and form a subunit of a disulfide-
linked homotrimeric protein. Study of human aortic
smooth muscle cells (HASMC) has revealed that TSP-1 is
involved in the migration and proliferation of HASMC,
moreover, the upregulation of TSP-1 by leptin is depended
on JAK2 and MAPK pathways [67]. Activated movement
of smooth muscle cell and migration/movement of endo-
thelial cell may imply phenotypic modulation of those
cells. Neuropilin 1 (NRP1), validated to be targeted by
miR-1 [66], participates in several different types of signal-
ing pathways that control cell migration, for example,
NRP1 binding with VEGF is essential for stimulation of
endothelial cell migration [68]. One of the crucial players
in the pathophysiology of IA is inflammation. Some stud-
ies at the transcriptome level are in accordance with the
histopathological series that associated endothelial dys-
function, loss of mural cells, inflammatory cell infiltration
and degradation of the matrix with sIA wall rupture [69].
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filtrate the aneurysm wall, a link between their presence
and aneurysm growth with subsequent rupture is not
completely understood [70]. 5 out of 12 functions are re-
lated to immune response, among those functions, migra-
tion of phagocytes, affected by 7 miRNAs and 11 genes,
has the highest potential to be activated. Genes validated
to interact with miRNA include PNP, MYC, CD276,
PIM1, THBS1, F11R and PLAU etc. which are involved in
immune response. For example, purine nucleoside phos-
phorylase (PNP) targeted by miR-1 [71], is associated with
T-cell (cell-mediated) immunity, B-cell immunity and anti-
body responses [72].
Functional analysis revealed some molecules targeted
miRNAs with high prediction, validation of the relation-
ship between the miRNA and these predicted targets are
necessary for extending the molecular network of IA.
Some upregulated genes expressed in intracranial arter-
ies including NLR family, tumor necrosis factor (ligand)
superfamily, interleukin, fibronectin and chemokine are
predicted targets of down-regulated miRNAs in our study.
Previous studies have implied their importance in IA
[11,57]. NLRP1, predicted target of miR-143-3p, is a mem-
ber of the Ced-4 family of apoptosis proteins that could
induce caspase-1 activation through the assembly of in-
flammasomes, multiprotein complexes, which are critical
for generating mature proinflammatory cytokines includ-
ing IL-1β and IL18. IL18 is also a predicted target of miR-
143-3p, which increase early stage apoptosis of cultured
HUVEC (umbilical vein endothelial cells) cells [73], and
increase the death of VEC [74]. Another apoptosis related
gene is TNFSF15, predicted target of miR-145-5p, which
belongs to the tumor necrosis factor (TNF) ligand family
acts as an autocrine factor to induce apoptosis in endothe-
lial cells by activating NF-kappaB and MAP kinases [75].
FN1, targeted by miR-1, is involved in cell adhesion and
migration processes. Two cytokine, CCL2 and CCL7, were
targeted by miR-1, miR-23a-3p and miR-143-3p respec-
tively. CCL2 displays chemotactic activity for monocytes
and basophils which has been implicated in the pathogen-
esis of atherosclerosis which is characterized by monocytic
infiltrates [76]. CCL7 is a secreted chemokine which at-
tracts macrophages during inflammation and metastasis
[77]. Although their interactions with miRNAs are pre-
dicted, validation the interactions in IA tissue could un-
earth the pivotal role of miRNAs in the pathogenesis of IA.
Limitation
This study has several limitations. One limitation is that
only end-stage of disease tissues are available, as only
the human IA samples are large enough or ruptured and
need surgical intervention can be obtained. IA dome
contains different cell type and tissues, the contribution
of misregulated genes in each cell type should be furtherdetermined. Our functional analyses were based on miRNA
targets which include highly predicted and experimentally
validated, so these highly predicted interactions should be
validated in future research.
Conclusion
Our data clearly showed the differential expression of 18
miRNAs in IA tissue from a control group of human
MMA tissue. Bio-informatic analysis by IPA indicates that
miRNAs target genes which may play a role in functional
changes in VEC and VSMC, and activation of inflammatory
response, and loss of cells in vessel wall. Our study was in
line with many previous studies, several candidates need to
be studied thoroughly to uncover the role of miRNA in IA.
Our study provides novel evidence identifying miRNAs in-
volved with response of the rupture of IA and gives us a
deeper understanding on pathology of IA, miRNA found in
this study may be a notably potential entry point to reveal
pathology of IA from another perspective.
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